|23rd February 2021||Stephen J Tulipano||5,000||Exercise of derivative||$4.48||$22,400.00|
|23rd February 2021||Stephen J Tulipano||5,000||Open or private sale||$58.60||$292,991.50|
|22nd February 2021||Stephen J Tulipano||25,000||Exercise of derivative||$4.48||$112,000.00|
|22nd February 2021||Stephen J Tulipano||102||Open or private sale||$60.00||$6,120.00|
|22nd February 2021||Stephen J Tulipano||15,202||Open or private sale||$58.67||$891,942.39|
|22nd February 2021||Stephen J Tulipano||9,696||Open or private sale||$59.29||$574,841.90|
|19th February 2021||Arthur Tzianabos||10,000||Open or private sale||$60.67||$606,652.00|
|19th February 2021||Arthur Tzianabos||10,000||Exercise of derivative||$2.19||$21,900.00|
|8th February 2021||Investments, Lp Rtw||3,650,722||Conversion of derivative||$0.00|
|4th February 2021||Investments, Lp Rtw||625,000||Open or private purchase||$16.00||$10,000,000.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Stoke Therapeutics, Inc. engages in the research and development of treatments for genetic diseases. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.